# A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

> **NCT07120984** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 52 (estimated)

## Conditions studied

- Glioma

## Interventions

- **BIOLOGICAL:** L19TNF
- **BIOLOGICAL:** L19TNF and TMZ
- **BIOLOGICAL:** L19TNF and CCNU
- **BIOLOGICAL:** L19TNF monotherapy
- **BIOLOGICAL:** L19TNF and TMZ in recurrent astrocytoma
- **BIOLOGICAL:** L19TNF and CCNU in recurrent astrocytoma
- **BIOLOGICAL:** L19TNF monothery in recurrent oligodendroglioma

## Key facts

- **NCT ID:** NCT07120984
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2029-01-30
- **Final completion:** 2029-01-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120984, "A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07120984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*